Join today and have your say! It’s FREE!

We will not release or resell your information to third parties without your permission.

Please Try Again

{{ error }}

By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Please Try Again

{{ error }}

Password Hint : {{passwordHint}}

Remember me

Forgot Password?

or

Privacy Policy | Disclaimer

Quote | Bullboard | News | Opinion | Profile | Peers | Filings | Financials | Options | Price History | Ratios | Ownership | Insiders | Valuation

Breaking & Recent News Pfizer Inc PFE

Alternate Symbol(s): N.PFE

Healthcare

Pfizer Inc. is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products worldwide. Its Biopharma segment is engaged in the science-based biopharmaceutical business. Its Biopharma segment includes the Pfizer Oncology Division, the Pfizer U.S. Commercial Division, and the... see more

Add To Watchlist

Recent & Breaking News (NYSE:PFE)

Apple Earnings In Focus, But Fed Meeting, Auto Sales Also Could Grab Headlines

Benzinga.com May 2, 2017

Investors: Covered Call reports for Exelixis, Facebook, Priceline, Pfizer Inc. and AT&T include trade ideas that offer returns of 18% or more!

PR Newswire May 2, 2017

A Peek Into The Markets: U.S. Stock Futures Mostly Lower; Apple Earnings In Focus

Benzinga.com May 2, 2017

PFIZER REPORTS FIRST-QUARTER 2017 RESULTS

Business Wire May 2, 2017

12 Stocks To Watch For May 2, 2017

Benzinga.com May 2, 2017

Feuerstein On Neurotrope: The Study Failed And There Was Never 'A Lot Of Hope Here'

Benzinga.com May 1, 2017

Looking For Action? Week Ahead Brings Heavy Load With Earnings, Data, Fed Meeting

Benzinga.com May 1, 2017

Pfizer Hosts Annual Meeting of Shareholders

Business Wire April 27, 2017

Pfizer’s Next-Generation ALK/ROS1 Inhibitor, Lorlatinib, Granted Breakthrough Therapy Designation from FDA for ALK-Positive Metastatic Non-Small Cell Lung Cancer

Business Wire April 27, 2017

Aquinnah Pharmaceuticals Receives $10 Million Investment from Pfizer and AbbVie to Research Breakthrough Approach to Neurodegenerative Disease

PR Newswire April 25, 2017

Pivotal Phase III Study Underscores Efficacy Of Zavicefta™ (ceftazidime-avibactam) For Treatment Of Hospital-Acquired Pneumonia, A Leading Cause Of Mortality In Hospitals

Business Wire April 24, 2017

Pfizer Receives Positive CHMP Opinion for BESPONSA® (Inotuzumab Ozogamicin) for the Treatment of Relapsed or Refractory Acute Lymphoblastic Leukemia

Business Wire April 21, 2017

Pfizer Unveils ATLAS®, An Interactive, User-Friendly Website That Provides Global Antibiotic Resistance Surveillance Data Across 60 Countries

Business Wire April 21, 2017

Pfizer Invites Public To Listen To Webcast Of April 27 Annual Meeting Of Shareholders

Business Wire April 20, 2017

Healthcare Sector Earnings: Making A Comeback In Q1 2017?

Benzinga.com April 12, 2017

Cardiovascular Players Could Be Eyeing Esperion

Benzinga.com April 10, 2017

Drug Makers Stocks on Investors' Radar -- Pfizer, Merck, Johnson & Johnson, and AbbVie

PR Newswire April 10, 2017

FDA Warns Of Dangerous Hidden Ingredient In 5 OTC Male Sexual Enhancement Supplements

Benzinga.com April 7, 2017

Global Oncology Market Gains Ground, Driven by Innovative Cancer Treatment Therapies

PR Newswire April 6, 2017

IBRANCE® (palbociclib) Receives FDA Regular Approval and Expanded Indication for First-Line HR+, HER2- Metastatic Breast Cancer

Business Wire March 31, 2017